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A range of chiral, optically-enriched bicyclic oxabispidines were
prepared from (S)-(-)-2,3-epoxypropylphthalimide using an eﬃcient
sequence featuring a stereocontrolled intramolecular Mannich
reaction as the key transformation.
Over recent years, molecules possessing both the bispidine
(1; X = CH2; Fig. 1) and oxabispidine (1; X = O) unit have
been shown to display a range of biological properties that
have made them attractive targets for the pharmaceutical
industry. For instance bispidines have been employed in
aa4b2 nicotinic acetylcholine receptor ligands as potential
neuroprotective agents,1 and the oxabispidine ring system
(1; X = O) has been strategically embedded within molecules
showing a range of potential medicinal applications, including use
as atrial repolarisation-delaying agents in the treatment of cardiac
arrhythmia (AstraZeneca),2 mTOR and PI3 kinase inhibitors
(Wyeth),3 P2X7 receptor antagonists/interleukin-1b inhibitors
(AstraZeneca),4 and Factor Xa inhibitors (GlaxoSmithKline).5
The lupine alkaloid, ()-sparteine 2,6 also has the bispidine
structure (1; X = CH2) at its core, with this natural product
having been employed as the key chiral ligand in an extensive
array of enantioselective transformations.7
Indeed, the rigid and central 3,7-diazabicyclo[3.3.1]nonane
backbone within ()-sparteine 2 is believed to be crucial to
the chiral induction within such asymmetric processes (vide infra).8
In contrast, chiral oxabispidines (1; X = O) have been the
focus of signiﬁcantly less attention as ligands for use in
enantioselective organic reactions, despite the potentially
similar chiral environment predicting that these species could
act as eﬀective surrogates for the bispidine-based, sparteine 2.
Although some stereoselective routes to oxabispidines have
emerged recently, the available methods tend to be limited by
(i) the requirement for more than one pre-formed chiral substrate,
(ii) relatively lengthy synthetic pathways, and (iii) a lack of
ﬂexibility relating to the substituent groups that can be
introduced around the oxabispidine core.9
As part of a search for eﬃcient methods of preparing
oxabispidines,10 we disclosed11 the intramolecular Mannich
cyclisation of oxazine 3 shown in Scheme 1.12,13
Based on this established precedent, we envisaged that
preparation of chiral amine 11 and engagement with a range
of higher aldehydes would potentially open expedient access
to a series of optically-enriched and further functionalised
oxabispidines. According to this strategy and as depicted in
Scheme 2, commercially available (S)-()-2,3-epoxypropyl-
phthalimide 6 provided the key chiral starting material. This
species underwent ring opening with amine 7; following a solvent
swap to toluene and addition of catalytic acid, heating at reﬂux
Fig. 1 Bridged bicyclic diamines 1 and 2.
Scheme 1 Intramolecular Mannich cyclisation.
Scheme 2 Preparation of amine precursor 11. Reaction Conditions a:
Ethanol, reﬂux; b: TsOH (10 mol%), toluene, reﬂux; c: ClCO2Bn,
CH2Cl2, r.t.; d: MeNH2, EtOH, reﬂux.
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resulted in cyclisation to form acetal 8.14 Prolonged exposure
to these conditions did not result in any further elimination of
methanol to give the oxazine. Consequently, conversion of the
benzylamine to the corresponding CBz protected amines 9 was
secured in a single step by treatment with benzylchloroformate.15
Exposure of 9 to reﬂuxing toluene/catalytic acid resulted in
smooth elimination to deliver oxazine 10 in 67% yield over
4 steps after silica gel chromatography. Whilst deprotection of
the phthalimide with hydrazine16 liberated 11 in an acceptable
70% yield, use of a more practically convenient procedure17 with
the less toxic methylamine delivered this key chiral unit 11 in a
more appreciable 87% yield without recourse to chromatography.
With amine 11 now readily accessible on scale, appropriate
conditions to allow a chemo- and stereoselective annulation
process were investigated.y Initially, the key chiral substrate 11
was coupled with a range of aldehydes to give imines 12,
generally as a single geometric (E) isomer. Following the
screening of a range of Lewis and Brønsted acids, under a
series of conditions, treatment of 12 with 1 molar equivalent of
triﬂuoromethanesulfonic acid (TfOH) at 20 1C resulted in
immediate consumption of the imine substrate. Although
isolation and characterisation of intermediate species so
formed was not possible, analysis by 1H NMR spectroscopy
indicated that neither the imine, nor the oxazine oleﬁnic
protons were present at this stage. Accordingly, addition of
1 molar equivalent of methanol resulted in formation of the
oxabispidine hemiaminal ether 13 (Scheme 3; Table 1), as a
single diastereomer in generally good to excellent yields.
The 1H NMR spectrum of 13a (which is typical of the series)
gives the appearance of a mixture of two isomers; variable
temperature studies showed that this is, in fact, due to
restricted rotation between stable conformations of the carbamate,
a feature also observable in the spectra of oxazines 10–12.
Careful assignment of spectra and nOe experiments revealed
that the R-substituent is disposed equatorially, and that the
–OMe group occupies an axial position. Conﬁrmation of these
assignments was provided by a single crystal X-ray diﬀractogram
of benzyl protected compound 14 (Fig. 2).18 Accordingly, these
outcomes are consistent with a chair-like transition state, as
shown in Scheme 4, in which the imine geometry is conserved,
followed by attack of methanol on the least hindered face of
the iminium ion.
As shown in Table 1, this cyclisation process was applied
successfully to a range of aldehydes. Notably, the imine
derived from electron-rich p-methoxybenzaldehyde did not
react under the standard TfOH conditions, with more forcing
conditions being required to deliver oxabispidine 13c (entry 3).
Additionally, although steric bulk does not appear to compromise
reactivity (entries 5 & 6), aldehydes bearing more than one
a-hydrogen did not work well (entry 7). This is attributable to
the propensity of amine 11 to catalyse competing aldol-type
polymerisation of the aldehyde. This drawback was overcome
by utilising Katritzky’s technique of stabilising reactive aldehydes
as the benzotriazole adduct.19 As shown in Scheme 5, addition of
one equivalent of benzotriazole, followed by the aldehyde, led to
formation of an intermediate with a complex 1H NMR spectrum
assigned as 15. Pleasingly, cyclisation to the oxabispidine acetal
16 occurred smoothly upon treatment with TfOH, although
full conversion required that the reaction be run for 18 h at r.t.
Additionally, within this revised protocol we discovered that
the liberated benzotriazole was a competent nucleophile,
leading to direct formation of the stable adduct 16.
With a view to accessing compounds of this class which
would have application in asymmetric synthesis, the further
functional manipulation of the product oxabispidines was
targeted. In this regard and as shown in Scheme 6, compounds
13a, c, and e, and 16 were treated with benzyl chloroformate,
followed by LAH to give the corresponding N,N0-dimethyl
Scheme 3 Formation of imines 12 and Mannich cyclisation to give
oxabispidine acetals 13.
Table 1 Scope of cyclisation and summary of oxabispidines prepared
Entry R Methoda Acetal Yield
1 Ph A 13a 92
2 o-BrC6H4 A 13b 96
3 p-MeOC6H4 B 13c 93
4 o-CF3C6H4 A 13d 76
5 tBu A 13e 90
6 c-Hex A 13f 76
7 nBu A — 0
8 nBu C 16 75
a Method A: CF3SO3H, MeOH, CH2Cl2, 20 1C to r.t.; B: p-TSA
(10 mol%), MeOH, 65 1C; C: CF3SO3H, BtH, CH2Cl2, 20 1C to r.t.
Fig. 2 The molecular structure of 14 with the thermal displacement
ellipsoids set at 50% probability and hydrogen atoms as spheres of
arbitrary radius.
Scheme 4 Postulated mechanistic pathway. Scheme 5 Preparation of oxabispidines from an aliphatic aldehyde.
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oxabispidines 18a, c, e, and g (R = Ph; p-MeOC6H4;
tBu; and
nBu, respectively) in good yields over two steps.
Compound 13a was chosen as a vehicle to demonstrate the
inherent ﬂexibility of this class of intermediate and, as shown
in Scheme 7, was eﬃciently converted to bis-2y amine 19, and
both complementary monomethyl compounds 20 and 21.
Having now established an eﬃcient route to optically-
enriched oxabispidine structures, the relationship of these
species with sparteine-type molecular architectures is worthy
of note. As recently shown by O’Brien, sparteine surrogates
(without the D ring unit) are superior to the full sparteine
structure within certain asymmetric applications.20 However,
access to ()-sparteine surrogates is not presently available. In
relation to this, structures 13/16 map directly onto the B/C
rings within ()-sparteine 2, whilst providing functionality to
allow further structural manipulations. Furthermore, employ-
ment of the commercially available enantiomeric (R)-glycidyl
phthalimide, (R)-6, will deliver the opposite chiral oxabispidine
series, equivalent to the known (+)-sparteine surrogates.7
These features add further to the preparative ﬂexibility and
utility of the routes developed here.
In summary, a range of C-substituted oxabispidines have
been prepared from a commercially available chiral building
block, using a novel stereoselective intramolecular Mannich
reaction. The route is highly modular and amenable to creation
of a wide range of analogues where diversity is incorporated late
in the synthetic sequence. Further studies directed towards the
stereoselective synthesis of other classes of bridged heterobicyclic
compounds with potential pharmaceutical and catalytic appli-
cations are ongoing within our laboratories.
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